The cardiotoxicity of hydrogen cyanide as a component of polymer pyrolysis smokes.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 6285553)

Published in Toxicol Appl Pharmacol on May 01, 1982

Authors

E J O'Flaherty, W C Thomas

Articles citing this

The challenge of fire effluents. BMJ (1990) 0.78

Articles by these authors

The effect of hypoparathyroidism on the aging skeleton. J Am Geriatr Soc (1990) 2.01

Administrative centralization versus decentralization and the role of generalists and specialists. Am J Public Health Nations Health (1968) 1.91

Control of crystallization in urine. Am J Med (1968) 1.66

The recognition and isolation from urine and serum of a peptide inhibitor to calcification. Johns Hopkins Med J (1967) 1.54

Effect of iodinated water supplies on thyroid function. J Clin Endocrinol Metab (1966) 1.12

Permanently decreased renal blood flow and hypertension after lithotripsy. N Engl J Med (1989) 1.07

A urinary peptide with extraordinary inhibitory powers against biological "calcification" (deposition of hydroxyapatite crystals). Trans Assoc Am Physicians (1966) 1.07

Urinary tract stone after small bowel bypass for morbid obesity. Am J Surg (1974) 1.06

Pyrophosphate and the mineralizing potential of urine. Clin Sci (1966) 1.05

Extracorporeal shock-wave lithotripsy: long-term complications. AJR Am J Roentgenol (1988) 1.01

Mineralization of human and bovine tissue in vitro. Am J Pathol (1967) 0.98

Effects of lead exposure on skeletal development in rats. Fundam Appl Toxicol (1994) 0.94

Dependence of apparent blood lead half-life on the length of previous lead exposure in humans. Fundam Appl Toxicol (1983) 0.94

Chemical mixtures from a public health perspective: the importance of research for informed decision making. Toxicology (1995) 0.94

A biomathematical model of particle clearance and retention in the lungs of coal miners. Regul Toxicol Pharmacol (2001) 0.92

Inhibition of mineralization by hydrolysates of phytic acid. Johns Hopkins Med J (1972) 0.92

Measurement of the flux of lead from bone to blood in a nonhuman primate (Macaca fascicularis) by sequential administration of stable lead isotopes. Fundam Appl Toxicol (1996) 0.91

Diplopia and loss of accommodation due to chloroquine. Arthritis Rheum (1970) 0.91

Urinary supersaturation with calcium oxalate before and during orthophosphate therapy. J Urol (1976) 0.88

The impact of air-lead on blood-lead in man--a critique of the recent literature. Food Cosmet Toxicol (1981) 0.87

Influence of lead on mineralization during bone growth. Fundam Appl Toxicol (1995) 0.87

Kidney stones, urine, and cement. Md Med J (1988) 0.87

Relationship between experimentally induced crystalluria and relative supersaturation of various stone salts in rats. Urol Res (1984) 0.86

The kinetics of urethane elimination in the mouse. Toxicol Appl Pharmacol (1983) 0.85

Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: a dose-effect study. Toxicol Appl Pharmacol (1985) 0.84

Abnormal diurnal variation of plasma cortisol in patients with renovascular hypertension. J Clin Endocrinol Metab (1967) 0.84

Parathyroid adenomas in chronic rickets. Am J Med (1970) 0.84

Effectiveness and mode of action of orthophosphates in patients with calcareous renal calculi. Trans Am Clin Climatol Assoc (1972) 0.82

Inorganic phosphates in the treatment of renal calculi. Mod Treat (1967) 0.82

Automated phosphorus method employing ferrous sulfate as the reducing agent. Am J Med Technol (1970) 0.82

Low-renin hypertension after extracorporeal shock wave lithotripsy. JAMA (1989) 0.81

Extracorporeal shock-wave lithotripsy. Ann Intern Med (1984) 0.81

Consideration of the mechanism of pulmonary adenogenesis in urethane-treated Swiss mice. Toxicol Appl Pharmacol (1984) 0.81

Some Observations on Rachitic Rat Cartilage of Probable Significance in the Etiology of Renal Calculi. Trans Am Clin Climatol Assoc (1959) 0.81

Fibrinogenesis imperfecta ossium. Trans Am Clin Climatol Assoc (1969) 0.81

The O'Flaherty model of lead kinetics: an evaluation using data from a lead smelter population. Toxicol Appl Pharmacol (1999) 0.80

The renal handling of delta-aminolevulinic acid in the rat and in the human. Toxicol Appl Pharmacol (1980) 0.80

Renal reabsorption and secretion of delta-aminolevulinic acid in the rat. Fundam Appl Toxicol (1983) 0.79

A system of exposing animals to smoke generated in a steady-state fashion. Environ Res (1980) 0.79

Symposium on renal lithiasis. Medical aspects of renal calculous disease. Treatment and prophylaxis. Urol Clin North Am (1974) 0.79

Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. II. Effects of Fe(III), Cr(III) and Al(III) complexes on calcium oxalate crystal growth. J Urol (1982) 0.78

Effects of an iodinated water supply. Trans Am Clin Climatol Assoc (1979) 0.78

Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. I. Effects of Fe(III), Cr(III) and Al(III) complexes on calcium phosphate crystal growth. J Urol (1982) 0.78

Evaluating lead bioavailability data by means of a physiologically based lead kinetic model. Fundam Appl Toxicol (1996) 0.78

Acetazolamide teratology and its association with carbonic anhydrase inhibition in the mouse. Teratog Carcinog Mutagen (1983) 0.78

Iodine disinfection of water. Arch Environ Health (1969) 0.78

Extracorporeal shock-wave lithotripsy: prevalence of renal stones 3-21 months after treatment. AJR Am J Roentgenol (1988) 0.78

Cushing's disease with cyclic hormonogenesis and diabetes insipidus. Neurosurgery (1979) 0.78

Aluminum-induced osteomalacia: an explanation. Am J Nephrol (1984) 0.77

Comparison of the maximum tolerated dose (MTD) dermal response in three strains of mice following repeated exposure to acrylic acid. Food Chem Toxicol (1995) 0.77

U.S. Environmental Protection Agency's revised cancer guidelines for carcinogen risk assessment. Toxicol Appl Pharmacol (1998) 0.76

Influence of aluminum on mineralization during matrix-induced bone development. Kidney Int (1986) 0.76

Effect of alkali administration on calcium metabolism. J Clin Endocrinol Metab (1967) 0.75

Genesis of osteomalacia following gastroenterostomy. Trans Am Clin Climatol Assoc (1967) 0.75

The effects of induced hypercalcemia on the activity of the parathyroid glands. Am J Pathol (1966) 0.75

Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds. Toxicol Sci (2000) 0.75

An essay on politics for health workers. Hosp Adm (Chic) (1975) 0.75

Review of 35 cases of hyperparathyroidism at the University of Florida. J Fla Med Assoc (1970) 0.75

Genetic toxicology of acrylic acid. Food Chem Toxicol (1992) 0.75

In memoriam John Eager Howard, M.D. J Clin Endocrinol Metab (1986) 0.75

Clinical concepts of renal calculous disease. J Urol (1975) 0.75

The rate of decline of blood lead in lead industry workers during medical removal: the effect of job tenure. Fundam Appl Toxicol (1986) 0.75

Trace metal-citric acid complexes as inhibitors of calcification and crystal formation. Proc Soc Exp Biol Med (1982) 0.75

Acute inhalation toxicity studies in several animal species of an ethylene oxide/propylene oxide copolymer (UCON 50-HB-5100). Drug Chem Toxicol (1991) 0.75

Kinetics of zinc absorption by the rat jejunum: effects of adrenalectomy and dexamethasone. Am J Physiol (1983) 0.75

Cytochrome c oxidase activity in tissues of rats exposed to polyurethane pyrolysis fumes. Toxicol Appl Pharmacol (1979) 0.75

Amino acids in urine and blood of calculous patients. Invest Urol (1981) 0.75

Relationship between urethan dose rate and adenoma latency: relevance of tumor growth rate and target cell number. J Natl Cancer Inst (1982) 0.75

In memoriam John Eager Howard, M.D. Endocrinology (1986) 0.75

Urinary tract calculi. Ann Intern Med (1968) 0.75

Aluminum and aluminum complexes. Effect on calcium phosphate precipitation. Kidney Int Suppl (1986) 0.75

Vitamin D deficiency in Florida, the Sunshine State. J Fla Med Assoc (1989) 0.75

Ghetto medicine from a political standpoint. Am J Public Health (1972) 0.75

A proposal for revision of curriculums of schools of public health. Public Health Rep (1969) 0.75

Corticosteroids. Int Anesthesiol Clin (1968) 0.75

Alterations of rat adipose tissue metabolism associated with dietary chromium supplementation. J Nutr (1978) 0.75

Letter: Iatrogenic socioeconopathy. N Engl J Med (1976) 0.75

Snowmobilopathy. N Engl J Med (1972) 0.75

The cardiotoxicity of carbon monoxide as a component of polymer pyrolysis smokes. Toxicol Appl Pharmacol (1982) 0.75

The effect of dexamethasone on the kinetics of jejunal zinc uptake and metallothionein synthesis in the rat. Dev Toxicol Environ Sci (1982) 0.75

The effect of extracorporeal shock wave lithotripsy on blood pressure. JAMA (1990) 0.75

Clinical studies in thyroiditis. Ann Intern Med (1965) 0.75

Thyroid disease. Int Anesthesiol Clin (1968) 0.75

Use of phosphates in patients with calcareous renal calculi. Kidney Int (1978) 0.75

Effect of thyroparathyroidectomy in hypercalcemia associated with malignancy. Endocrinology (1967) 0.75

The surgical amelioration of endocrine exophthalmos. Surgery (1967) 0.75

The expectation gap and the stereotype of the stereotype: images of old people. Gerontologist (1981) 0.75

Resistance of the rat to development of lead-induced renal functional deficits. J Toxicol Environ Health (1986) 0.75

The subchronic oral toxicity of polyphenylene sulfide. J Appl Toxicol (1984) 0.75

Right renal trauma: a side effect of biliary lithotripsy. N Engl J Med (1989) 0.75

Effect of vitamin D in fluoride-treated rats. Clin Orthop Relat Res (1978) 0.75

Walter Reed in Florida. Trans Am Clin Climatol Assoc (1973) 0.75

Approaches to national health planning. Public Health Pap (1972) 0.75

Inhalation teratology studies of n-butyl mercaptan in rats and mice. Fundam Appl Toxicol (1987) 0.75

Effects of cadmium on salamander survival and limb regeneration. Environ Res (1978) 0.75

Evaluation of the genetic activity of industrially produced carbon black. J Toxicol Environ Health (1981) 0.75

Relationship of lung adenoma prevalence and growth rate to acute urethan dose and target cell number. J Natl Cancer Inst (1982) 0.75